Transdermal oestradiol for androgen suppression in prostate cancer: long-term cardiovascular outcomes from the randomised Prostate Adenocarcinoma Transcutaneous Hormone (PATCH) trial programme

BACKGROUND: Androgen suppression is a central component of prostate cancer management but causes substantial long-term toxicity. Transdermal administration of oestradiol (tE2) circumvents first-pass hepatic metabolism and, therefore, should avoid the cardiovascular toxicity seen with oral oestrogen...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Lancet
Main Authors: Langley, Ruth E, Gilbert, Duncan C, Duong, Trinh, Clarke, Noel W, Nankivell, Matthew, Rosen, Stuart D, Mangar, Stephen, Macnair, Archie, Sundaram, Subramanian Kanaga, Laniado, Marc E, Dixit, Sanjay, Madaan, Sanjeev, Manetta, Caroline, Pope, Alvan, Scrase, Christopher D, Mckay, Stephen, Muazzam, Iqtedar A, Collins, Gerald N, Worlding, Jane, Williams, Simon T, Paez, Edgar, Robinson, Angus, McFarlane, Jonathan, Deighan, John V, Marshall, John, Forcat, Silvia, Weiss, Melanie, Kockelbergh, Roger, Alhasso, Abdulla, Kynaston, Howard, Parmar, Mahesh
Formato: Artigo
Idioma:Inglês
Publicado em: 2021
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7614681/
https://ncbi.nlm.nih.gov/pubmed/33581820
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/S0140-6736(21)00100-8
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados